Porton Pharma

Chongqing Porton Pharma Solutions Co., Ltd. was established in 2005 and is a leading domestic contract development and manufacturing organization (CDMO) for pharmaceuticals. In 2014, it was listed on the Shenzhen Stock Exchange (stock code: 300363). The company primarily provides global pharmaceutical companies and drug R&D institutions with custom R&D and manufacturing services for chemical drugs, biologics, and formulations throughout the entire drug lifecycle, from early clinical research to market launch. As a national high-tech enterprise, we offer world-class end-to-end CDMO services to global clients. Our R&D, manufacturing, and operations span across Chongqing, Chengdu, Shanghai, Jiangxi, Suzhou, Hong Kong (China), the United States, Belgium, Switzerland, and the United Kingdom, with over 3,000 employees worldwide.
We are committed to becoming the world's most open, innovative, and reliable pharmaceutical service platform, enabling better medicines to benefit the public sooner. Through over a decade of dedication, we have built strong R&D technology platforms, comprehensive quality management, EHS management systems, and a proven delivery record. We provide core services to global innovative drug companies, ranging from pilot-scale to commercial production and various certification, registration, and approval support. We have passed NMPA, FDA, PMDA, WHO, and EMA certifications, serving renowned pharmaceutical companies and drug R&D institutions worldwide. Our product portfolio includes blockbuster drugs with annual global sales exceeding $1 billion, covering therapeutic areas such as AIDS, hepatitis, diabetes, tumors, pain management, heart failure, blood lipid lowering, insomnia, epilepsy, influenza, and allergies.
We persist in driving high-quality development through technological innovation, continuously increasing R&D investment, and actively advancing key core technology development and the cultivation of innovative talent teams. In 2020, R&D investment reached RMB 158 million, with an R&D team exceeding 700 members. As of the end of 2020, the company had been granted 40 invention patents (31 domestic and 9 international) and 4 PCT patents.
We leverage over a decade of experience in serving multinational pharmaceutical companies and our internationally excellent CDMO platform to actively support domestic drug development and accelerate the drug approval process. We provide comprehensive services to domestic pharmaceutical companies and drug R&D institutions, including innovative drug CMC services, MAH commissioned manufacturing, clinical trial services, custom R&D and manufacturing of innovative drug intermediates, APIs, and formulations, as well as gene and cell therapy CDMO services. We are progressively building an open, collaborative CDMO platform that excels in both "technological innovation" and "service innovation."